SCHEMBL584239

SCHEMBL584239

C[SiH](C)OC([C@H]1CN(c2ccc(OC[C@H]3C[C@H]4COc5c(c(F)cc6c(=O)c(C(=O)OCc7ccccc7)cn(C7CC7)c56)N4C3)c(F)c2)C(=O)O1)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.33
KCNH2 Q12809 2/20 0.32
GSK3B P49841 1/20 0.31
HDAC3 O15379 3/20 0.31
TUBB4A P04350 3/20 0.31
TUBB P07437 3/20 0.31
TUBA3C P0DPH7 3/20 0.31
HDAC4 P56524 3/20 0.31
TUBA1B P68363 3/20 0.31
TUBA4A P68366 3/20 0.31
TUBB4B P68371 3/20 0.31
TUBB3 Q13509 3/20 0.31
HDAC1 Q13547 3/20 0.31
TUBB2A Q13885 3/20 0.31
TUBB8 Q3ZCM7 3/20 0.31
TUBA3E Q6PEY2 3/20 0.31
TUBA1A Q71U36 3/20 0.31
HDAC7 Q8WUI4 3/20 0.31
HDAC2 Q92769 3/20 0.31
HDAC10 Q969S8 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL583981 1.00 STAT3 (0.33) STAT3KCNH2GSK3BHDAC3TUBB4A
SCHEMBL584427 0.88 STAT3 (0.36) STAT3KCNH2GSK3BHDAC3TUBB4A
SCHEMBL2527925 0.88 STAT3 (0.36) STAT3KCNH2GSK3BHDAC3TUBB4A
SCHEMBL584975 0.88 STAT3 (0.36) STAT3KCNH2GSK3BHDAC3TUBB4A
SCHEMBL584974 0.88 STAT3 (0.36) STAT3KCNH2GSK3BHDAC3TUBB4A
SCHEMBL2528001 0.87 TUBB4A (0.34) STAT3KCNH2GSK3BHDAC3TUBB4A
SCHEMBL2531196 0.87 TUBB4A (0.34) STAT3KCNH2GSK3BHDAC3TUBB4A
SCHEMBL583982 0.87 STAT3 (0.33) STAT3KCNH2GSK3BHDAC3TUBB4A
SCHEMBL584240 0.87 STAT3 (0.33) STAT3KCNH2GSK3BHDAC3TUBB4A
SCHEMBL2841091 0.84 MAOA (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2102217-B1 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS ACTELION PHARMACEUTICALS LTD (CH) 2012-02-15 EP disclosed
US-8039466-B2 5-hydroxymethyl-oxazolidin-2-one antibacterials ACTELION PHARMACEUTICAL LTD. (CH) 2011-10-18 US disclosed
US-20100069376-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS ACTELION PHARMACEUTICALS, LTD. (CH) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069376-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS OGFOD1, ODC1, OXGR1 STAT3 4566/4885KCNH2 594/4885GSK3B 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.